Ossifying fibromyxoid tumor of soft parts: A clinicopathologic, proteomic, and genomic study

American Journal of Surgical Pathology

Volumn 35, Issue 11, 2011, Pages 1615-1625

  Graham, Rondell P D ^a   Dry, Sarah ^b   Li, Xinmin ^b   Binder, Scott ^b   Bahrami, Armita ^c   Raimondi, Susana C ^c   Dogan, Ahmet ^a   Chakraborty, Subhankar ^d   Souchek, Joshua J ^d   Folpe, Andrew L ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

fluorescence in situ hybridization; gene expression profiling; immunohistochemistry; INI 1; ossifying fibromyxoid tumor of soft parts; proteomics

Indexed keywords

TUMOR MARKER;

ADULT; ARTICLE; BIOPSY; CHEMISTRY; CLINICAL TRIAL; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; OSSIFYING FIBROMA; PATHOLOGY; PROGNOSIS; PROTEOMICS; SOFT TISSUE TUMOR; TANDEM MASS SPECTROMETRY; UNITED STATES;

ADULT; BIOPSY; CHROMATOGRAPHY, LIQUID; FEMALE; FIBROMA, OSSIFYING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROGNOSIS; PROTEOMICS; SOFT TISSUE NEOPLASMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 80055009975     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182284a3f     Document Type: Article

References (39)

1. Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol. 2006;30:436-443. (Pubitemid 43740143)
2. Ahmad FJ, Yu W, McNally FJ, et al. An essential role for katanin in severing microtubules in the neuron. J Cell Biol. 1999;145:305-315. (Pubitemid 29198303)
3. Asher RA, Morgenstern DA, Shearer MC, et al. Versican is upregulated in CNS injury and is a product of oligodendrocyte lineage cells. J Neurosci. 2002;22:2225-2236. (Pubitemid 35386522)
4. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59:74-79. (Pubitemid 29062960)
5. Biegel JA, Fogelgren B, Zhou JY, et al. Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system. Clin Cancer Res. 2000;6:2759-2763. (Pubitemid 30482115)
6. Chbani L, Guillou L, Terrier P, et al. Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol. 2009;131:222-227.
7. Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65:1-105. (Pubitemid 32479155)
8. Donner LR. Ossifying fibromyxoid tumor of soft parts: evidence supporting Schwann cell origin. Hum Pathol. 1992;23:200-202.
9. Doyle LA, Moller E, Mertens F, et al. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Mod Pathol. 2011;24(Supplement 1):12A.
10. Enzinger FM, Weiss SW, Liang CY. Ossifying fibromyxoid tumor of soft parts. A clinicopathological analysis of 59 cases. Am J Surg Pathol. 1989;13:817-827. (Pubitemid 19246217)
11. Fisher C, Hedges M, Weiss SW. Ossifying fibromyxoid tumor of soft parts with stromal cyst formation and ribosome-lamella complexes. Ultrastruct Pathol. 1994;18:593-600. (Pubitemid 24357402)
12. Fletcher CD, Unni KK, Mertens F. Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.
13. Folpe AL, Weiss SW. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic study of 70 cases with emphasis on atypical and malignant variants. Am J Surg Pathol. 2003;421-431. (Pubitemid 36368539)
14. Furuta A, Rothstein JD, Martin LJ. Glutamate transporter protein subtypes are expressed differentially during rat CNS development. J Neurosci. 1997;17:8363-8375. (Pubitemid 27461059)
15. Gutmann DH. The neurofibromatoses: when less is more. Hum Mol Genet. 2001;10:747-755. (Pubitemid 32331584)
16. Hirose T, Shimada S, Tani T, et al. Ossifying fibromyxoid tumor: invariable ultrastructural features and diverse immunophenotypic expression. Ultrastruct Pathol. 2007;31:233-239. (Pubitemid 47037186)
17. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009;33:542-550.
18. Kilpatrick SE, Ward WG, Mozes M, et al. Atypical and malignant variants of ossifying fibromyxoid tumor. Clinicopathologic analysis of six cases. Am J Surg Pathol. 1995;19:1039-1046.
19. Kohashi K, Oda Y, Yamamoto H, et al. Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol. 2010;23:981-990.
20. Miettinen M. Ossifying fibromyxoid tumor of soft parts. Additional observations of a distinctive soft tissue tumor. Am J Clin Pathol. 1991;95:142-149.
21. Miettinen M, Finnell V, Fetsch JF. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic and immunohistochemical study of 104 cases with long-term follow-up and a critical review of the literature. Am J Surg Pathol. 2008;32:996-1005.
22. Min KW, Seo IS, Pitha J. Ossifying fibromyxoid tumor: modified myoepithelial cell tumor? Report of three cases with immunohistochemical and electron microscopic studies. Ultrastruct Pathol. 2005;29:535-548. (Pubitemid 41769941)
23. Modena P, Lualdi E, Facchinetti F, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res. 2005;65:4012-4019. (Pubitemid 40775637)
24. Nishio J, Iwasaki H, Ohjimi Y, et al. Ossifying fibromyxoid tumor of soft parts: cytogenetic findings. Cancer Genet Cytogenet. 2002;133:124-128. (Pubitemid 34279643)
25. Orrock JM, Abbott JJ, Gibson LE, et al. INI1 and GLUT-1 expression in epithelioid sarcoma and its cutaneous neoplastic and nonneoplastic mimics. Am J Dermatopathol. 2009;31:152-156.
26. Patil S, Perry A, Maccollin M, et al. Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol. 2008;18:517-519.
27. Rodriguez FJ, Gamez JD, Vrana JA, et al. Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest. 2008;88:1024-1037.
28. Schaffler G, Raith J, Ranner G, et al. Radiographic appearance of an ossifying fibromyxoid tumor of soft parts. Skeletal Radiol. 1997;26:615-618. (Pubitemid 27472478)
29. Schofield JB, Krausz T, Stamp GW, et al. Ossifying fibromyxoid tumour of soft parts: immunohistochemical and ultrastructural analysis. Histopathology. 1993;22:101-112. (Pubitemid 23067130)
30. Shet T, Desai S, Kane S, et al. Nerve cell markers in ossifying fibromyxoid tumour of soft parts. Indian J Pathol Microbiol. 2001;44:163-167. (Pubitemid 33700410)
31. Sheth S, Li X, Binder S, et al. Differential gene expression profiles of neurothekeomas and nerve sheath myxomas by microarray analysis. Mod Pathol. 2011;24:343-354.
32. Swartz MJ, Batra SK, Varshney GC, et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol. 2002;117:791-796. (Pubitemid 34457016)
33. Uno K, Takita J, Yokomori K, et al. Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors. Genes Chromosomes Cancer. 2002;34:33-41. (Pubitemid 34260594)
34. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203-206. (Pubitemid 28325977)
35. Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114: 4957-4959.
36. Weiss SW, Goldblum JR. Enzinger & Weiss's Soft Tissue Tumors. Mosby: Elsevier; 2008.
37. Williams SB, Ellis GL, Meis JM, et al. Ossifying fibromyxoid tumour (of soft parts) of the head and neck: a clinicopathological and immunohistochemical study of nine cases. The J Laryngol Otol. 1993;107:75-80. (Pubitemid 23217258)
38. Yoshida H, Minamizaki T, Yumoto T, et al. Ossifying fibromyxoid tumor of soft parts. Acta Pathologica Japonica. 1991;41:480-486.
39. Zamecnik M, Michal M, Simpson RH, et al. Ossifying fibromyxoid tumor of soft parts: a report of 17 cases with emphasis on unusual histological features. Ann Diagn Pathol. 1997;1:73-81. (Pubitemid 127683353)